Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis shows survival benefits of new advanced breast cancer therapy

Novartis shows survival benefits of new advanced breast cancer therapy

11th October 2016

Novartis has announced new clinical trial data that demonstrates the advantages of its new treatment regime for advanced breast cancer.

Results from the phase III MONALEESA-2 study showed the investigational LEE011, when added to the standard of care letrozole, significantly extended progression-free survival as a first-line treatment in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced or metastatic breast cancer.

LEE011 plus letrozole reduced the risk of death or progression by 44 percent over letrozole alone, with these benefits observed across all patient subgroups, regardless of disease characteristics or demographics.

Moreover, it was shown that more than half of women with measurable disease taking LEE011 plus letrozole saw their tumour size shrink by at least 30 percent as a result of treatment.

Bruno Strigini, chief executive officer for Novartis Oncology, said: "We look forward to working closely with health authorities to bring a much-needed new treatment option to these patients as quickly as possible."

LEE011 was developed by the Novartis Institutes for BioMedical Research through a research collaboration with Astex Pharmaceuticals. The drug was granted a breakthrough therapy classification by the US Food and Drug Administration in August.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801826576-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.